Clinical Trials

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

A phase II umbrella trial in patients with relapsed ovarian cancer.

Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial Including LOGOS (Low Grade Ovarian Cancer Sub-study).

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer

A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high grade ovarian cancer patientS in first line therapy

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer 

A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Randomized, multicenter, open-label, phase 3 study of mirvetuximab
soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer 

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer 

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. 

An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer 

A phase 3 multicenter randomized staudy of Atezolizumab vs placebo administered in combination with Paclitaxel,Carboplatin and Bevacizumab to patients with newly diagnosed stage III or stage IV ovarian, fallopian tube or primary peritoneal cancer

IntraPeritoneal therapy for Ovarian Cancer with Carboplatin (GOTIC-001 / JGOG3019) 

A phase II study of neoadjuvant chemotherapy plus tremelimumab and durvalumab in advanced-stage ovarian cancer

A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer.